Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127779362> ?p ?o ?g. }
- W2127779362 abstract "Background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Some epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutations make tumours responsive to treatment with EGFR-TK inhibitors (EGFR-TKIs) but less responsive to treatment with standard chemotherapy. Patients with NSCLC are therefore tested for EGFR-TK tumour gene mutations to inform treatment decisions. There are a variety of tests available to detect these mutations. The different tests vary in the specific mutations that they attempt to detect, the amount of tumour cells needed for the test to work, the time that it takes to give a result, the error rate of the test, and the cost of the test. Objective To compare the performance and cost-effectiveness of EGFR-TK mutation tests used to identify previously untreated adults with locally advanced or metastatic NSCLC, who may benefit from first-line treatment with TKIs. Data sources Twelve databases to August 2012 [including MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations and Daily Update (OvidSP), EMBASE, Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment database (HTA), Science Citation Index (SCI), Latin American and Caribbean Health Sciences Literature (LILACS), BIOSIS Previews, NIHR Health Technology Assessment programme, PROSPERO (International Prospective Register of Systematic Reviews)], research registers and conference proceedings. A web-based survey gathered data on technical performance of EGFR-TK mutation tests. Methods Randomised controlled trials were assessed for methodological quality using the Cochrane risk of bias tool. Diagnostic accuracy studies were assessed using QUADAS-2. There were insufficient data for meta-analysis. For accuracy studies, we calculated sensitivity and specificity together with 95% confidence intervals (CIs). Survival data were summarised as hazard ratios and tumour response data as relative risks, with 95% CIs. The health-economic analysis considered the long-term costs and quality-adjusted life-years (QALYs) associated with different tests followed by treatment with either standard chemotherapy or a TKI. Direct sequencing was taken as the comparator. The de novo model consisted of a decision tree and a Markov model. Results The survey indicated no differences between tests in batch size, turnaround time, number of failed samples or cost. Six studies provided data on the accuracy of EGFR-TK mutation testing for predicting response to treatment with TKIs. Estimates of accuracy were similar across studies. Six analyses provided data on the clinical effectiveness of TKIs compared with standard chemotherapy. There were no clear differences in the treatment effects reported by different studies, regardless of which EGFR mutation test was used to select patients. Cost-effectiveness analysis using ‘Evidence on comparative effectiveness available’ and ‘Linked evidence’ approaches: Therascreen® EGFR polymerase chain reaction (PCR) Kit (Qiagen, Venlo, the Netherlands) was both less effective and less costly than direct sequencing of all exon 19–21 mutations at an incremental cost-effectiveness ratio of £32,167 (comparative) and £32,190 (linked) per QALY lost. ‘Assumption of equal prognostic value’ approach: the lowest total strategy cost was [commercial-in-confidence (CiC) information has been removed] [Sanger sequencing or Roche cobas EGFR Mutation Testing Kit® (Roche Molecular Systems, Inc., Branchburg, NJ, USA)] compared with (CiC information has been removed) for the most expensive strategy (fragment length analysis combined with pyrosequencing). Limitations The cost-effectiveness analysis assumed that the differences in outcomes between the results of the trials were solely attributable to the different mutation tests used to distinguish between patients; this assumption ignores other factors that might explain this variation. Conclusion There was no strong evidence that any one EGFR mutation test had greater accuracy than any other test. Re-testing of stored samples from previous studies, where patient outcomes are already known, could be used to provide information on the relative effectiveness of TKIs and standard chemotherapy in patients with EGFR mutation-positive and mutation-negative tumours, where mutation status is determined using tests for which adequate data are currently unavailable. Study registration PROSPERO CRD42012002828. Funding The National Institute for Health Research Health Technology Assessment programme." @default.
- W2127779362 created "2016-06-24" @default.
- W2127779362 creator A5001156294 @default.
- W2127779362 creator A5012940159 @default.
- W2127779362 creator A5021404933 @default.
- W2127779362 creator A5058135669 @default.
- W2127779362 creator A5059685514 @default.
- W2127779362 creator A5065584931 @default.
- W2127779362 creator A5065740152 @default.
- W2127779362 creator A5074205715 @default.
- W2127779362 creator A5077388783 @default.
- W2127779362 date "2014-05-01" @default.
- W2127779362 modified "2023-09-25" @default.
- W2127779362 title "Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis" @default.
- W2127779362 cites W128476255 @default.
- W2127779362 cites W1589127617 @default.
- W2127779362 cites W1593173821 @default.
- W2127779362 cites W1667731616 @default.
- W2127779362 cites W1931438814 @default.
- W2127779362 cites W1969116196 @default.
- W2127779362 cites W1970433797 @default.
- W2127779362 cites W1971737397 @default.
- W2127779362 cites W1972451626 @default.
- W2127779362 cites W1973269051 @default.
- W2127779362 cites W1973551917 @default.
- W2127779362 cites W1973644773 @default.
- W2127779362 cites W1973849995 @default.
- W2127779362 cites W1975276584 @default.
- W2127779362 cites W1977211995 @default.
- W2127779362 cites W1977657955 @default.
- W2127779362 cites W1980278982 @default.
- W2127779362 cites W1981359437 @default.
- W2127779362 cites W1982397643 @default.
- W2127779362 cites W1988257756 @default.
- W2127779362 cites W1988442083 @default.
- W2127779362 cites W1991481804 @default.
- W2127779362 cites W1992983339 @default.
- W2127779362 cites W1995714163 @default.
- W2127779362 cites W2005111569 @default.
- W2127779362 cites W2005728761 @default.
- W2127779362 cites W2006558502 @default.
- W2127779362 cites W2006915001 @default.
- W2127779362 cites W2008013090 @default.
- W2127779362 cites W2010515258 @default.
- W2127779362 cites W2011019372 @default.
- W2127779362 cites W2014785602 @default.
- W2127779362 cites W2016136864 @default.
- W2127779362 cites W2017128352 @default.
- W2127779362 cites W2017479165 @default.
- W2127779362 cites W2018475895 @default.
- W2127779362 cites W2018832622 @default.
- W2127779362 cites W2023816433 @default.
- W2127779362 cites W2028269517 @default.
- W2127779362 cites W2030864655 @default.
- W2127779362 cites W2032573089 @default.
- W2127779362 cites W2035121233 @default.
- W2127779362 cites W2035813468 @default.
- W2127779362 cites W2036894259 @default.
- W2127779362 cites W2040336929 @default.
- W2127779362 cites W2043683360 @default.
- W2127779362 cites W2043696829 @default.
- W2127779362 cites W2043826980 @default.
- W2127779362 cites W2045486039 @default.
- W2127779362 cites W2046510435 @default.
- W2127779362 cites W2048379155 @default.
- W2127779362 cites W2050647940 @default.
- W2127779362 cites W2051575509 @default.
- W2127779362 cites W2051899693 @default.
- W2127779362 cites W2054133698 @default.
- W2127779362 cites W2054909337 @default.
- W2127779362 cites W2056659899 @default.
- W2127779362 cites W2060299515 @default.
- W2127779362 cites W2063056853 @default.
- W2127779362 cites W2063337513 @default.
- W2127779362 cites W2065703103 @default.
- W2127779362 cites W2068864761 @default.
- W2127779362 cites W2070258228 @default.
- W2127779362 cites W2071374645 @default.
- W2127779362 cites W207778065 @default.
- W2127779362 cites W2078943728 @default.
- W2127779362 cites W2081269875 @default.
- W2127779362 cites W2083299269 @default.
- W2127779362 cites W2084437976 @default.
- W2127779362 cites W2089545132 @default.
- W2127779362 cites W2092063599 @default.
- W2127779362 cites W2092232609 @default.
- W2127779362 cites W2094173295 @default.
- W2127779362 cites W2095618958 @default.
- W2127779362 cites W2098923148 @default.
- W2127779362 cites W2101055110 @default.
- W2127779362 cites W2104603750 @default.
- W2127779362 cites W2106585301 @default.
- W2127779362 cites W2107638293 @default.
- W2127779362 cites W2107791134 @default.
- W2127779362 cites W2111662961 @default.
- W2127779362 cites W2114232665 @default.
- W2127779362 cites W2114461323 @default.
- W2127779362 cites W2116308061 @default.
- W2127779362 cites W2120598067 @default.
- W2127779362 cites W2122890773 @default.